Lipid-lowering agents in chronic kidney disease: do fibrates have a role?

被引：0
|
作者：
Yuli Huang
Yunzhao Hu
机构：
[1] the Affiliated Hospital at Shunde (the First People's Hospital of Shunde),Department of Cardiology
[2] Southern Medical University,undefined
来源：
Nature Reviews Cardiology | 2013年 / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：547 / 547
相关论文
共 50 条
  • [1] Lipid-lowering agents in chronic kidney disease: do fibrates have a role?
    Huang, Yuli
    Hu, Yunzhao
    NATURE REVIEWS CARDIOLOGY, 2013, 10 (09) : 547 - 547
  • [2] Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
    Katsiki, Niki
    Mikhailidis, Dimitri P.
    Banach, Maciej
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (16) : 2007 - 2017
  • [3] LIPID-LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?
    Green, Darren
    Panayotova, Rosica
    Ritchie, James P.
    O'Riordan, Edmond
    McDonald, John
    JOURNAL OF RENAL CARE, 2012, 38 (03) : 138 - 146
  • [4] Lipid-lowering therapy in chronic kidney disease
    Fernández-Vega, F
    NEFROLOGIA, 2004, 24 (06): : 113 - 126
  • [5] Lipid-lowering therapy in patients with chronic kidney disease
    Walker, R
    NEPHROLOGY, 2005, 10 : S231 - S234
  • [6] Efficiency and safety of lipid-lowering therapy for chronic kidney disease
    Kolina, I. B.
    Stavrovskaya, E. V.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (06) : 73 - 77
  • [7] Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs
    Vito M. Campese
    Clinical and Experimental Nephrology, 2014, 18 : 291 - 295
  • [8] Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs
    Campese, Vito M.
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2014, 18 (02) : 291 - 295
  • [9] Psychiatric Adverse Reactions with Statins, Fibrates and EzetimibeImplications for the Use of Lipid-Lowering Agents
    Michael Tatley
    Ruth Savage
    Drug Safety, 2007, 30 : 195 - 201
  • [10] Lipid-Lowering Agents
    Ewang-Emukowhate, Mfon
    Wierzbicki, Anthony S.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 18 (05) : 401 - 411
12345